ImmunoGen initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Joseph Catanzaro started ImmunoGen with an Overweight rating and $15 price target. The analyst says the company’s wholly-owned oncology asset is nearing a pivotal readout.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.